Scalper1 News
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics’ sales more than doubled over the year-earlier quarter to $113 million, some $16 million higher than consensus. The loss of 49 cents a share was well below consensus of 22 cents, but analysts don’t attach much significance to that number since it includes stock-based Scalper1 News
Scalper1 News